

Never stop discovering Limitless Ultrasound Imaging with the new Esaote MyLab™X8 at BMUS 2019

December 10, 2019 [Harrogate, UK] - Esaote presents the **MyLab[™]X8** - the high-performance and versatile ultrasound platform to support hospitals and clinics facing today's challenges - at **BMUS 2019**, the 51st Annual Scientific Meeting of the British Medical Ultrasound Society, **booth number 1-4** (December 10th- 12th, Harrogate Convention Center, United Kingdom).

Based on the recently introduced ULTRA[™] technology platform, the product profile includes a limitless approach to ultrasound imaging and high-quality patient care.

"The **new MyLab**"X8 is designed to be a reliable partner in the daily clinical routine," said **Luca Bombino**, Ultrasound Global Marketing Director at Esaote. "We leveraged scalable technology to completely renew our ultrasound product line, and migrate premium performance and features to more affordable systems, without compromising clinical confidence, throughput, and reliability."

Esaote has always invested in workflow-oriented design. The new **MyLab™X8** has many solutions in common with the MyLab™9, its flagship ultrasound product, from the control panel design to the automated functions, such as the **easyMode**^{*} and **easyColor**^{*} that are two exclusive Esaote solutions which simplify and drive ultrasound image optimization in just 3 swipes.

The MyLab[™]X8 platform includes a wide range of cutting-edge technologies, such as:

- CnTI[™] and QPack for contrast imaging and quantification
- Virtual Navigator fusion imaging to combine ultrasound with a second modality
- QElaXto shearwave elastography
- microV for slow flow detection

As in the **MyLab™9** platform, the new MyLab[™]X8 integrates the **easyScanning** functions package that includes the eScan, eDoppler and easyMode tools, in order to simplify the image optimization, reduce the examination times and increase the clinical confidence.

The latest release **EVO3 full liver package** on Esaote's **MyLab™9 eXP** further improves the solution for ultrasound liver examinations.

The QElaXto and QElaXto 2D features deliver an accurate quantitative measurement of the tissue stiffness based on an innovative approach to evaluate shear-wave propagation and velocity.

The latest EVO3 also brings more sensitivity to CEUS applications with a new version of the CnTI[™] option and interventional activities can be conducted with the Virtual Navigator, the Esaote 3D fusion solution.

Moreover, the new "**Never Stop Seeing the Unseen**." concept highlights the Esaote's attitude to innovation, research, and development, affirming the Italian company as one of the world's leading providers of diagnostic imaging solutions.

Come and discover the new MyLab[™]X8 and MyLab[™]9 eXP on December 10th- 12th at ESAOTE BOOTH 1-4.

* patent pending

MyLab[™]X8 is 510(k) pending at FDA, not available for sale in the United States.

MyLab is a trademark of Esaote spa. Technology and features are system/configuration dependent. Specifications are subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.

About Esaote

The Esaote Group is a leader in the biomedical equipment sector, in particular in the areas of ultrasound, dedicated MRI, and software for managing the diagnostic process. The company currently employs about 1,120 people. With its headquarters in Genoa and its own production and research units in Italy and the Netherlands, Esaote is active in 80 countries in the world. Information on Esaote and its products is available at <u>www.esaote.com</u>

© Copyright Esaote 2019